As drug discovery efforts advance, prioritizing brain-permeable, cell-type-specific, and chronically safe Nrf2 modulators will be critical for translating these findings into effective, disease-modifying therapies for ALS. This evidence concerns the gene NFE2L2 and amyotrophic lateral sclerosis.